<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421196</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00236914</org_study_id>
    <nct_id>NCT04421196</nct_id>
  </id_info>
  <brief_title>Opioid-free Total Hip Arthroplasty</brief_title>
  <official_title>Opioid-free Total Hip Arthroplasty: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of investigators' proposed study is to demonstrate that the following
      two cohorts undergoing total hip arthroplasty will have equivalent visual analog scale (VAS)
      scores up to 3 months post-operatively: one that is administered a modified multimodal
      analgesic pathway without opioids and the other administered the current standard multimodal
      analgesic pathway used at Johns Hopkins Bayview Hospital (which includes opioids). The
      secondary objective is to demonstrate that these cohorts will also have equivalent functional
      outcomes as determined by both objective measures (such as hip range of motion) and
      patient-reported outcome measures, such as the Hip Disability and Osteoarthritis Outcome
      Score (HOOS) and the University of California at Los Angeles (UCLA) activity score.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in post-operative pain assessed by the Visual analog scale (VAS) pain scores</measure>
    <time_frame>From immediate post-operative period to 3 months post-operatively</time_frame>
    <description>Post-operative pain scores ranging from 0 to 10; 0 being no pain and 10 being the worst pain ever felt</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain satisfaction as assessed by Hip Disability and Osteoarthritis Outcome Score (HOOS)</measure>
    <time_frame>From pre-operative clinic visit to immediate post-operative period, then to 3 months post-operatively</time_frame>
    <description>A patient-reported measure that assesses components such as assesses patient pain, satisfaction including stiffness and range of motion, activity limitations-daily living, sports and recreation function, and quality of life. Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Activity level as assessed by the University of California at Los Angeles (UCLA) Scale</measure>
    <time_frame>From pre-operative clinic visit to immediate post-operative period, and then to 3 months post-operatively</time_frame>
    <description>The UCLA scale is a patient-reported measure ranging from 1 to 10. Patients indicate their most appropriate activity level, with 1 defined as &quot;no physical activity, dependent on others&quot; and 10 defined as &quot;regular participation in impact sports.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Standard multimodal analgesic pathway with opioids</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.
The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) &amp; Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified multimodal analgesic pathway without opioids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.
The modified multimodal analgesic regimen utilizes the following medications:
includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exclusion of opioid analgesics</intervention_name>
    <description>The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.</description>
    <arm_group_label>Modified multimodal analgesic pathway without opioids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of all ages with end-stage primary hip osteoarthritis.

        Exclusion Criteria:

          -  Patients with creatinine clearance between 30 and 60 mL/min

          -  Use of any opioid analgesics in the 6 months preceding surgery

          -  Revision total hip arthroplasty

          -  Patients with liver insufficiency

          -  Patients on chronic anticoagulation

          -  Workers compensation patients

          -  Patients who cannot receive Acetaminophen, Ketorolac, Celecoxib, or Gabapentin for any
             reason (e.g. allergies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julius Oni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kawsu Barry, M.D.</last_name>
    <phone>3202238080</phone>
    <email>kbarry16@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julius Oni, M.D.</last_name>
    <phone>4105505397</phone>
    <email>joni1@jhmi.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Madras BK. The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations. Clin Pharmacol Ther. 2018 Jun;103(6):943-945. doi: 10.1002/cpt.1050. Epub 2018 Mar 23.</citation>
    <PMID>29570781</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Merchan EC, Vaquero-Picado A, Ruiz-Perez JS. Correction to: Opioid-Free Total Knee Arthroplasty? Local Infiltration Analgesia Plus Multimodal Blood-Loss Prevention Make it Possible. HSS J. 2019 Jul;15(2):209. doi: 10.1007/s11420-019-09679-x. Epub 2019 Apr 1.</citation>
    <PMID>31327956</PMID>
  </reference>
  <reference>
    <citation>Leas DP, Connor PM, Schiffern SC, D'Alessandro DF, Roberts KM, Hamid N. Opioid-free shoulder arthroplasty: a prospective study of a novel clinical care pathway. J Shoulder Elbow Surg. 2019 Sep;28(9):1716-1722. doi: 10.1016/j.jse.2019.01.013. Epub 2019 May 6.</citation>
    <PMID>31072655</PMID>
  </reference>
  <reference>
    <citation>Desmet M, Vermeylen K, Van Herreweghe I, Carlier L, Soetens F, Lambrecht S, Croes K, Pottel H, Van de Velde M. A Longitudinal Supra-Inguinal Fascia Iliaca Compartment Block Reduces Morphine Consumption After Total Hip Arthroplasty. Reg Anesth Pain Med. 2017 May/Jun;42(3):327-333. doi: 10.1097/AAP.0000000000000543.</citation>
    <PMID>28059869</PMID>
  </reference>
  <reference>
    <citation>Stevens RD, Van Gessel E, Flory N, Fournier R, Gamulin Z. Lumbar plexus block reduces pain and blood loss associated with total hip arthroplasty. Anesthesiology. 2000 Jul;93(1):115-21.</citation>
    <PMID>10861154</PMID>
  </reference>
  <reference>
    <citation>Becchi C, Al Malyan M, Coppini R, Campolo M, Magherini M, Boncinelli S. Opioid-free analgesia by continuous psoas compartment block after total hip arthroplasty. A randomized study. Eur J Anaesthesiol. 2008 May;25(5):418-23. Epub 2007 Nov 21.</citation>
    <PMID>18028577</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

